Complementary and Alternative Therapies for Genitourinary Syndrome of Menopause : An Evidence Map.

Ullman KE, Diem S, Forte ML, Ensrud K, Sowerby C, Zerzan N, Anthony M, Landsteiner A, Greer N, Butler M, Wilt TJ, Danan ER. Complementary and Alternative Therapies for Genitourinary Syndrome of Menopause : An Evidence Map. Annals of internal medicine. 2024 Oct 1; 177(10):1389-1399.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

BACKGROUND: Women seeking nonhormonal interventions for vulvovaginal, urinary, and sexual symptoms associated with genitourinary syndrome of menopause (GSM) may seek out complementary and alternative medicine or therapies (CAMs). PURPOSE: To summarize published evidence of CAMs for GSM. DATA SOURCES: Ovid MEDLINE, EMBASE, and CINAHL from inception through 11 December 2023. STUDY SELECTION: Randomized controlled trials (RCTs) 8 weeks or more in duration that evaluated the effectiveness or harms of CAMs for postmenopausal women with GSM and reported 1 or more outcomes of interest, with sample sizes of 20 or more participants randomly assigned per group. DATA EXTRACTION: Data were abstracted by 1 reviewer and verified by a second. DATA SYNTHESIS: An evidence map approach was used to organize and describe trials. Studies were organized by type of intervention, with narrative summaries for population, study characteristics, interventions, and outcomes. Fifty-seven trials were identified that investigated 39 unique interventions. Studies were typically small (? < 200), and most were done in Iran ( = 24) or other parts of Asia ( = 9). Few trials evaluated similar combinations of populations, interventions, comparators, or outcomes. Most studies ( = 44) examined natural products (that is, herbal or botanical supplements and vitamins), whereas fewer reported on mind and body practices ( = 6) or educational programs ( = 7). Most studies reported 1 or 2 GSM symptoms, mainly sexual ( = 44) or vulvovaginal ( = 30). Tools used to measure outcomes varied widely. Most trials reported on adverse events ( = 33). LIMITATIONS: Only English-language studies were used. Effect estimates, risk of bias, and certainty of evidence were not assessed. CONCLUSION: There is a large and heterogeneous literature of CAM interventions for GSM. Trials were small, and few were done in North America. Standardized population, intervention, comparator, and outcomes reporting in future RCTs are needed. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality and Patient-Centered Outcomes Research Institute. (PROSPERO: CRD42023400684).